Pfizer director Ronald E. Blaylock acquires $499,072 in stock
Ronald E. Blaylock, a director at Pfizer Inc. (NYSE:PFE), purchased 19,457 shares of the company's common stock. The ...
Hosted on MSN43m
Pfizer’s Talzenna gains 14-months OS lead over mCRPC SoC
Results from the company’s Talapro-2 trial saw a 38% reduction in the risk of death among HRR-mutated patients.